Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Exactech (EXAC) Stock Price
Media stories about Exactech (NASDAQ:EXAC) have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Exactech earned a daily sentiment score of 0.03 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 47.6918458660113 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- Great Basin Scientific (GBSN) & Exactech (EXAC) Head-To-Head Analysis (americanbankingnews.com)
- EXACTECH INVESTOR ALERT BY THE FORMER ATTORNEY… (benzinga.com)
- Monteverde & Associates PC Announces An Investigation Of Exactech, Inc. – EXAC (4-traders.com)
- SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Exactech, Inc. And Encourages Investors To Contact The Firm For Additional Information (finance.yahoo.com)
- EXACTECH INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exactech, Inc. (finance.yahoo.com)
Shares of Exactech (NASDAQ EXAC) traded down 0.36% during mid-day trading on Monday, reaching $41.70. 592,539 shares of the company traded hands. The firm has a 50-day moving average price of $33.45 and a 200 day moving average price of $30.67. The firm has a market capitalization of $598.31 million, a price-to-earnings ratio of 801.92 and a beta of 1.01. Exactech has a 52 week low of $22.20 and a 52 week high of $42.55.
Exactech (NASDAQ:EXAC) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.33. Exactech had a net margin of 7.25% and a return on equity of 7.96%. The company had revenue of $67.30 million for the quarter, compared to the consensus estimate of $67.75 million. During the same quarter in the prior year, the company earned $0.31 EPS. Exactech’s quarterly revenue was up 1.8% on a year-over-year basis. On average, analysts anticipate that Exactech will post $1.30 earnings per share for the current year.
A number of brokerages have recently commented on EXAC. Robert W. Baird set a $34.00 price target on shares of Exactech and gave the stock a “buy” rating in a research note on Sunday, October 15th. Zacks Investment Research lowered shares of Exactech from a “hold” rating to a “sell” rating in a research note on Wednesday, October 25th. Gabelli lowered shares of Exactech from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. BidaskClub lowered shares of Exactech from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Finally, Sidoti lowered shares of Exactech from a “buy” rating to a “neutral” rating in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating and four have given a hold rating to the stock. The company has a consensus rating of “Hold” and an average target price of $42.00.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Exactech (EXAC) Stock Price” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://theolympiareport.com/2017/10/30/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-exactech-exac-stock-price.html.
In related news, Director Fern Watts sold 1,013 shares of the stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $29.04, for a total value of $29,417.52. Following the transaction, the director now owns 4,727 shares in the company, valued at approximately $137,272.08. The sale was disclosed in a filing with the SEC, which is available through this link. 28.30% of the stock is currently owned by corporate insiders.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.